Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)

Summary

This is a Phase III, multicenter, global, open-label, single-arm, retreatment study of an investigational drug called galiximab in combination with an approved drug called rituximab in subjects with relapsed or refractory, follicular NHL who demonstrated a response on Study 114-NH-301 with a time-to-progression \>=6 months.

Timeline

Start

2007-11

Primary completion

2010-01

Completion

2010-01

Outcome

Outcome not reported

Stopped (Enrollment): “Enrollment challenges due to changes in standards of care resulted in premature termination. No safety or efficacy events factored into this action.”

Drugs

Indications